Construction of chimeric E3s expression plasmids targeting oncoprotein ras.

Area of Science:

• Molecular Biology
• Oncology
• Biotechnology

Background:

• Oncoprotein Ras plays a critical role in various cancers.
• Targeting Ras for protein knockdown is a promising therapeutic strategy.
• Developing efficient expression systems for protein knockdown is essential.

Purpose of the Study:

• To construct chimeric E3 ubiquitin ligase (E3) expression plasmids targeting oncoprotein Ras.
• To utilize protein knockdown theory for Ras inhibition.
• To create a foundation for further research in Ras-targeted therapies.

Main Methods:

• Chimeric E3 plasmids were engineered using specific binding and functional domains (Raf-1, PI3K, RalGDS, F-Box, U-Box).
• Plasmid integrity and nucleotide fragment cloning were validated using double enzyme digestion, PCR, and sequencing.
• Expression efficiency in eukaryotic cells (HEK293T) was assessed via Western blot analysis.

Main Results:

• Five out of six constructed plasmids successfully expressed fusion proteins in HEK293T cells.
• The plasmid (RBD+CRD)(Raf-1)-U-Box-pcDNA3.1 demonstrated the ability to effectively knock down Ras protein levels in PANC-1 cells.

Conclusions:

• Novel chimeric E3 expression plasmids targeting Ras were successfully constructed.
• These plasmids provide a robust platform for investigating protein knockdown strategies against Ras.
• This research lays the groundwork for developing new cancer treatments focused on Ras inhibition.